check_circleStudy Completed
Deep vein thrombosis (DVT), Pulmonary embolism (PE)
Bayer Identifier:
11702
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
EU CT Number:
Not Available
The EINSTEIN DVT study
Trial purpose
Primary Objective:
To evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA (VKA: either warfarin or acenocoumarol) in the treatment of subjects with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolic events.
Secondary Objective:
The principal safety objective was the evaluation of major and clinically relevant non-major bleeding events.
To evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA (VKA: either warfarin or acenocoumarol) in the treatment of subjects with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolic events.
Secondary Objective:
The principal safety objective was the evaluation of major and clinically relevant non-major bleeding events.
Key Participants Requirements
Sex
AllAge
18 - 95 YearsTrial summary
Enrollment Goal
3449Trial Dates
March 2007 - April 2010Phase
Phase 3Could I Receive a placebo
N/AProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
NoTrial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
TreatmentAllocation
RandomizedBlinding
N/AAssignment
Parallel AssignmentTrial Arms
N/A